title: Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
abstract: BACKGROUND
  Developing a vaccine against HCV is an important medical and global priority. Unavailability and potential dangers associated with using attenuated HCV viral particles for vaccine preparation have resulted in the use of HCV genes and proteins formulated in novel vaccine modalities.
  
  
  METHODS
  In part one of this review, advances in basic knowledge for HCV vaccine design were provided. Herein, a detailed and correlated patents (searched by Espacenet) and literatures (searched by Pubmed) review on HCV vaccine formulations and modalities is provided, including: subunit, DNA, epitopic-peptide/polytopic, live vector- and whole yeast-based vaccines. Less-touched areas in vaccine studies such as mucosal, plant-based, and chimeric HBV/HCV vaccines are also discussed. Furthermore, results of preclinical/clinical studies on selected HCV vaccines as well as pros and cons of different strategies are reviewed. Finally, potential strategies for creation and/or improvement of HCV vaccine formulations are discussed.
  
  
  CONCLUSIONS
  Promising outcomes of a few HCV vaccine modalities in phase I/II clinical trials predict the accessibility of at least partially effective vaccines to inhibit or treat the chronic state of HCV infection (specially in combination with standard antiviral therapy). ChronVac-C (plasmid DNA), TG4040 (MVA-based), and GI-5005 (whole yeast-based) might be the most obvious HCV vaccine candidates to be approved in the near future.
authors.affiliation: Hepatitis & AIDS Department, Pasteur Institute of Iran, Tehran, Iran. rfarzin@pasteur.ac.ir
authors.forename: Farzin
authors.initials: F
authors.lastname: Roohvand
authors.forename: Niloufar
authors.initials: N
authors.lastname: Kossari
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D002626:Chemistry, Pharmaceutical; D015195:Drug Design; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology*; D006526:Hepatitis C / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D010330:Patents as Topic; D019444:Vaccines, DNA / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000737:chemistry / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D014761:Viral Hepatitis Vaccines